A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementiaShifu Xiao, Raoli He, Ying Peng et al.|Alzheimer s Research & Therapy|2021Cited by 200
Identification of genetic risk factors in the Chinese population implicates a role of immune system in Alzheimer’s disease pathogenesisXiaopu Zhou, Marek M. Mesulam, Yu Chen et al.|Proceedings of the National Academy of Sciences|2018Cited by 103
Does parity matter in women’s risk of dementia? A COSMIC collaboration cohort studyJong Bin Bae, John D. Crawford, Darren M. Lipnicki et al.|BMC Medicine|2020Cited by 79
Plasma Aβ42/Aβ40 and p-tau181 Predict Long-Term Clinical Progression in a Cohort with Amnestic Mild Cognitive ImpairmentZhenxu Xiao, Qianhua Zhao, Wanqing Wu et al.|Clinical Chemistry|2022Cited by 32
Plasma Aβ42/Aβ40 and p‐tau181 are associated with clinical progression in amnestic mild cognitive impairment: An 8‐year longitudinal studyZhenxu Xiao, Ding Ding, Wanqing Wu et al.|Alzheimer s & Dementia|2023Cited by 0